To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
Taisho was established in 1912 to produce over-the-counter drugs. The company moved into prescription drug R&D in 1955.
The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, and others. In prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed Abbott Laboratories.
Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange where its security code is 4535. Principal owners of the firm are the Uehara family.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Taisho_Pharmaceutical". A list of authors is available in Wikipedia.|